Valuation: CSL Limited

Market Cap 58.37B 50.07B 46.75B 42.89B 80.66B 5,579B 81.99B 552B 216B 2,798B 219B 214B 9,251B P/E 2027 *
19.5x
P/E 2028 * 17.7x
Enterprise Value 67.5B 57.9B 54.06B 49.6B 93.28B 6,451B 94.81B 638B 250B 3,236B 253B 248B 10,698B EV / Sales 2027 *
4.3x
EV / Sales 2028 * 4.13x
Free-Float
99.97%
Yield 2027 *
2.53%
Yield 2028 * 2.68%
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.41%+3.68%+41.39%-1.04% 83.96B
+2.84%+24.49%-22.44%-35.85% 56.76B
+0.85%-0.32%-1.93%+30.25% 51.35B
-0.37%-0.96%+11.17%+166.26% 48.41B
-0.38%+4.55%+58.45%-16.92% 32.74B
-18.02%+124.96%+432.48%+28.90% 69.62B
+0.24%+6.57%+49.00%+97.97% 26.04B
+3.00%+6.36%+6.92%+224.88% 21.81B
-1.20%+2.54%+61.86%+124.17% 17.11B
Average -1.46%+24.15%+70.77%+68.74% 45.31B
Weighted average by Cap. -2.55%+34.60%+91.10%+45.41%

Financials

2027 *2028 *
Net sales 15.7B 13.47B 12.58B 11.54B 21.7B 1,501B 22.05B 148B 58.11B 753B 58.95B 57.67B 2,488B 16.23B 13.92B 13B 11.93B 22.43B 1,552B 22.8B 153B 60.08B 778B 60.95B 59.62B 2,573B
Net income 2.82B 2.42B 2.26B 2.07B 3.89B 269B 3.96B 26.63B 10.43B 135B 10.58B 10.35B 447B 3.16B 2.71B 2.53B 2.32B 4.36B 302B 4.43B 29.83B 11.68B 151B 11.85B 11.59B 500B
Net Debt 9.13B 7.83B 7.31B 6.71B 12.62B 873B 12.82B 86.28B 33.79B 438B 34.28B 33.53B 1,447B 8.73B 7.49B 6.99B 6.42B 12.07B 835B 12.27B 82.53B 32.32B 419B 32.79B 32.07B 1,384B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-